HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...

November 08, 2024

Vol.50 No.42

In Brief

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer

Incyte announced early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.

September 06, 2024

Vol.50 No.33

Clinical Roundup

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

IMUNON Inc., a clinical-stage company in late-stage development of its DNA-mediated immunotherapy, announced positive topline results from the phase II OVATION 2 study with IMNN-001 in patients with advanced ovarian cancer.

August 02, 2024

Vol.50 No.31

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

YOU MAY BE INTERESTED IN

Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

Renew today!

Subscriber content

Login